| 1 | treatment-related | 1,713 |
| 2 | false | 1,682 |
| 3 | gram | 1,218 |
| 4 | drug-related | 1,090 |
| 5 | treatment-emergent | 870 |
| 6 | dose-limiting | 338 |
| 7 | solicited | 282 |
| 8 | intolerable | 209 |
| 9 | next-generation | 153 |
| 10 | medication-related | 129 |
| 11 | opioid-related | 116 |
| 12 | vaccine-related | 112 |
| 13 | unsolicited | 106 |
| 14 | chemotherapy-related | 92 |
| 15 | giemsa | 92 |
| 16 | therapy-related | 90 |
| 17 | infusion-related | 88 |
| 18 | coagulase | 86 |
| 19 | treatment-associated | 83 |
| 20 | nonhematologic | 77 |
| 21 | dna-dna | 66 |
| 22 | intervention-related | 66 |
| 23 | study-related | 52 |
| 24 | non-hematological | 51 |
| 25 | nick-end | 47 |
| 26 | non-haematological | 46 |
| 27 | injection-related | 42 |
| 28 | muscle-related | 41 |
| 29 | investigator-reported | 36 |
| 30 | system-related | 36 |
| 31 | drug-associated | 32 |
| 32 | radiation-related | 30 |
| 33 | treatment-limiting | 29 |
| 34 | morphine-related | 28 |
| 35 | lobene | 27 |
| 36 | product-related | 23 |
| 37 | renal-related | 23 |
| 38 | toxicity-related | 22 |
| 39 | nonhematological | 20 |
| 40 | port-wine | 19 |
| 41 | therapy-associated | 19 |
| 42 | all-causality | 17 |
| 43 | antibiotic-related | 16 |
| 44 | bevacizumab-related | 16 |
| 45 | acupuncture-related | 13 |
| 46 | gastrointestinal-related | 13 |
| 47 | regimen-related | 13 |
| 48 | vaccine-associated | 13 |
| 49 | discontinuation-emergent | 12 |
| 50 | rt-related | 12 |
| 51 | art-related | 11 |
| 52 | cv-related | 11 |
| 53 | g3+ | 11 |
| 54 | infusion-associated | 11 |
| 55 | anaesthesia-related | 10 |
| 56 | analgesia-related | 10 |
| 57 | g3/4 | 10 |
| 58 | vaccination-related | 10 |
| 59 | 'false | 9 |
| 60 | cetuximab-related | 8 |
| 61 | cisplatin-associated | 8 |
| 62 | class-effect | 8 |
| 63 | any-grade | 7 |
| 64 | gi-related | 7 |
| 65 | grade≥3 | 7 |
| 66 | pi-associated | 7 |
| 67 | state-related | 7 |
| 68 | 'medically | 6 |
| 69 | drug-attributable | 6 |
| 70 | integument-related | 6 |
| 71 | psychiatric-related | 6 |
| 72 | ssri-related | 6 |
| 73 | temsirolimus-related | 6 |
| 74 | complication-related | 5 |
| 75 | heparin-related | 5 |
| 76 | metabolic-related | 5 |
| 77 | pump-related | 5 |
| 78 | 'screened | 4 |
| 79 | catumaxomab-related | 4 |
| 80 | events/serious | 4 |
| 81 | gravidic | 4 |
| 82 | hla-dq2/8 | 4 |
| 83 | ifn-associated | 4 |
| 84 | muscle-associated | 4 |
| 85 | nonlaboratory | 4 |
| 86 | oil-red-o | 4 |
| 87 | radiochemotherapy-related | 4 |
| 88 | rsv-rna | 4 |
| 89 | tamoxifen-related | 4 |
| 90 | adpkd-related | 3 |
| 91 | agent-related | 3 |
| 92 | amiodarone-related | 3 |
| 93 | capecitabine-related | 3 |
| 94 | cmi-related | 3 |
| 95 | cml-related | 3 |
| 96 | cmv-dna | 3 |
| 97 | crt-related | 3 |
| 98 | drugs-related | 3 |
| 99 | ecg-related | 3 |
| 100 | edema-related | 3 |
| 101 | epidural-related | 3 |
| 102 | heroin-related | 3 |
| 103 | hypothyroidism-induced | 3 |
| 104 | immunosuppression-related | 3 |
| 105 | interferon-related | 3 |
| 106 | ipt-related | 3 |
| 107 | lamotrigine-attributed | 3 |
| 108 | low-arousal | 3 |
| 109 | m₂r-mediated | 3 |
| 110 | negative-her2 | 3 |
| 111 | photoaffinity | 3 |
| 112 | post-cpoe | 3 |
| 113 | pre-intubation | 3 |
| 114 | program-related | 3 |
| 115 | provider-rated | 3 |
| 116 | sca-related | 3 |
| 117 | self-attributed | 3 |
| 118 | stimulant-related | 3 |
| 119 | tinnitus-evoked | 3 |
| 120 | topiramate-associated | 3 |
| 121 | trastuzumab-related | 3 |
| 122 | treatment-modifying | 3 |
| 123 | treatment-unrelated | 3 |
| 124 | tyrosine-hydroxylase | 3 |
| 125 | vancomycin-associated | 3 |
| 126 | 'hypersensitivity | 2 |
| 127 | /serious | 2 |
| 128 | 2,062 | 2 |
| 129 | 3,679 | 2 |
| 130 | 5-loci | 2 |
| 131 | abstinence-related | 2 |
| 132 | antiretroviral-related | 2 |
| 133 | arv-related | 2 |
| 134 | aαc-induced | 2 |
| 135 | cabozantinib-associated | 2 |
| 136 | chemotherapy-mediated | 2 |
| 137 | clozapine-associated | 2 |
| 138 | depletion-related | 2 |
| 139 | dihydroethedium | 2 |
| 140 | dual-column | 2 |
| 141 | eight-color | 2 |
| 142 | feminising | 2 |
| 143 | follow-up.no | 2 |
| 144 | gabapentin-related | 2 |
| 145 | gramm | 2 |
| 146 | her2-neu | 2 |
| 147 | hfpef-related | 2 |
| 148 | hr-related | 2 |
| 149 | hsp90-related | 2 |
| 150 | icatibant-related | 2 |
| 151 | ics-related | 2 |
| 152 | intra-cup | 2 |
| 153 | isoniazid-related | 2 |
| 154 | la-related | 2 |
| 155 | linifanib-related | 2 |
| 156 | lipodystrophy-related | 2 |
| 157 | mineralocorticoid-related | 2 |
| 158 | nevirapine-associated | 2 |
| 159 | nevirapine-induced | 2 |
| 160 | no-gi | 2 |
| 161 | nonanosmic | 2 |
| 162 | nut-related | 2 |
| 163 | o-antigenic | 2 |
| 164 | onabotulinumtoxina-associated | 2 |
| 165 | pdm-style | 2 |
| 166 | pemetrexed-related | 2 |
| 167 | ribavirin-related | 2 |
| 168 | rose-bengal | 2 |
| 169 | slit-related | 2 |
| 170 | snpstream | 2 |
| 171 | sypro-ruby | 2 |
| 172 | systemically-mediated | 2 |
| 173 | ta-related | 2 |
| 174 | tick-associated | 2 |
| 175 | vector-related | 2 |
| 176 | 'cardiometabolic | 1 |
| 177 | 'finger | 1 |
| 178 | -adrenergic-mediated | 1 |
| 179 | -improved | 1 |
| 180 | .haematological | 1 |
| 181 | .treatment-emergent | 1 |
| 182 | /s-rich | 1 |
| 183 | 0=very | 1 |
| 184 | 10/167 | 1 |
| 185 | 100. | 1 |
| 186 | 11,442 | 1 |
| 187 | 128/445 | 1 |
| 188 | 1bntiq-produced | 1 |
| 189 | 2-diphenylphosphinoyl-2,3-dien-1-ols | 1 |
| 190 | 25,946 | 1 |
| 191 | 38,530 | 1 |
| 192 | 60/625 | 1 |
| 193 | 69/70 | 1 |
| 194 | 7,736 | 1 |
| 195 | 94,459 | 1 |
| 196 | acitretin-associated | 1 |
| 197 | afatinib-related | 1 |
| 198 | aht-induced | 1 |
| 199 | alkylaniline-induced | 1 |
| 200 | almorexant-related | 1 |
| 201 | amotivation/asociality | 1 |
| 202 | analgesic-related | 1 |
| 203 | anthracyclines-induced | 1 |
| 204 | anticalcineurin | 1 |
| 205 | arousal-balanced | 1 |
| 206 | available.other | 1 |
| 207 | beta-agonist-mediated | 1 |
| 208 | blaper-1 | 1 |
| 209 | brdu/nestin | 1 |
| 210 | c4d-negative | 1 |
| 211 | calcineurin-inhibitor-induced | 1 |
| 212 | canada-common | 1 |
| 213 | cd34/cd133 | 1 |
| 214 | cd95-ligand | 1 |
| 215 | ces-related | 1 |
| 216 | chemical-level | 1 |
| 217 | ciliate-associated | 1 |
| 218 | classically-described | 1 |
| 219 | clinical/culture | 1 |
| 220 | cmab009-associated | 1 |
| 221 | cmi-linked | 1 |
| 222 | co2-reducing | 1 |
| 223 | coagulasa | 1 |
| 224 | cochlear-vestibular | 1 |
| 225 | continious | 1 |
| 226 | contrast-media-induced | 1 |
| 227 | conversion-related | 1 |
| 228 | cortisol-enforced | 1 |
| 229 | cq-related | 1 |
| 230 | d-late | 1 |
| 231 | denervation-related | 1 |
| 232 | desserting | 1 |
| 233 | dgge-band | 1 |
| 234 | diarrhea-attributable | 1 |
| 235 | dildl/lectin | 1 |
| 236 | discrepancy-related | 1 |
| 237 | dna–dna | 1 |
| 238 | docetaxel-specific | 1 |
| 239 | drug-attributed | 1 |
| 240 | drug-correlated | 1 |
| 241 | drugs.when | 1 |
| 242 | dsra-based | 1 |
| 243 | eea-related | 1 |
| 244 | effectsserious | 1 |
| 245 | ema-test | 1 |
| 246 | endoscopist-specific | 1 |
| 247 | enzymatiz | 1 |
| 248 | enzyme-containing | 1 |
| 249 | ertapenem-associated | 1 |
| 250 | erα- | 1 |
| 251 | estimate.in-hospital | 1 |
| 252 | ethanol-withdrawal-induced | 1 |
| 253 | event/serious | 1 |
| 254 | exome-enriched | 1 |
| 255 | extra-hematologic | 1 |
| 256 | extra-striate | 1 |
| 257 | ezatiostat-related | 1 |
| 258 | ezn-4176-related | 1 |
| 259 | facts-the | 1 |
| 260 | fda-requested | 1 |
| 261 | free-hand-drawn | 1 |
| 262 | g-gr-related | 1 |
| 263 | gi-gu | 1 |
| 264 | gold-induced | 1 |
| 265 | grass-associated | 1 |
| 266 | group.intraoperative | 1 |
| 267 | h2-oxidizing | 1 |
| 268 | haiderpur | 1 |
| 269 | hela-spiked | 1 |
| 270 | hematoxylin-eosine | 1 |
| 271 | hfs-related | 1 |
| 272 | hla/dr | 1 |
| 273 | hp-immune | 1 |
| 274 | hql-related | 1 |
| 275 | ifi-attributable | 1 |
| 276 | ifnβ-associated | 1 |
| 277 | igpro20-related | 1 |
| 278 | ihc2+/bdish | 1 |
| 279 | il-2-receptor | 1 |
| 280 | illumina-based | 1 |
| 281 | immunosuppressant-induced | 1 |
| 282 | imt-related | 1 |
| 283 | injection-site-related | 1 |
| 284 | irinotecan-associated | 1 |
| 285 | isospora- | 1 |
| 286 | klinisk | 1 |
| 287 | klüver-barrera | 1 |
| 288 | knowledge.no | 1 |
| 289 | l-carnitine-related | 1 |
| 290 | lactation-long | 1 |
| 291 | laronidase-related | 1 |
| 292 | leflunomide-associated | 1 |
| 293 | leuco-esterase | 1 |
| 294 | lorcaserin-related | 1 |
| 295 | mannitol-related | 1 |
| 296 | me-cya-induced | 1 |
| 297 | membrane-less | 1 |
| 298 | mild/absent | 1 |
| 299 | minitura | 1 |
| 300 | minor-related | 1 |
| 301 | mirtazapine-related | 1 |
| 302 | moderately-strong | 1 |
| 303 | monoviral | 1 |
| 304 | mtx-associated | 1 |
| 305 | multi-gated | 1 |
| 306 | myd88/pi3k-directed | 1 |
| 307 | ncic-tc | 1 |
| 308 | netilmicin-induced | 1 |
| 309 | newer-design | 1 |
| 310 | niacin-associated | 1 |
| 311 | nicked-end | 1 |
| 312 | nih-defined | 1 |
| 313 | nissel | 1 |
| 314 | nocebo-driven | 1 |
| 315 | nonbleached | 1 |
| 316 | nonmortal | 1 |
| 317 | nonnocturnal | 1 |
| 318 | nonpregnancy-specific | 1 |
| 319 | ntcp-predicted | 1 |
| 320 | ocular/non-ocular | 1 |
| 321 | omalizumab-related | 1 |
| 322 | opioid-type | 1 |
| 323 | over-detect | 1 |
| 324 | overuse-related | 1 |
| 325 | p2xv/trpv1 | 1 |
| 326 | pacemaker-related | 1 |
| 327 | palifermin-related | 1 |
| 328 | pamidronate-related | 1 |
| 329 | pancreatitis/glucose | 1 |
| 330 | panss-rated | 1 |
| 331 | papanicoulau | 1 |
| 332 | past-treatment | 1 |
| 333 | pazopanib-related | 1 |
| 334 | pf-3512676-related | 1 |
| 335 | pld-associated | 1 |
| 336 | pneumoperitoneus | 1 |
| 337 | positive-false | 1 |
| 338 | positive/false | 1 |
| 339 | possibly-related | 1 |
| 340 | ppar-related | 1 |
| 341 | pre-writing | 1 |
| 342 | prepharmacy | 1 |
| 343 | presented.serious | 1 |
| 344 | prilocaine-related | 1 |
| 345 | prone-related | 1 |
| 346 | prostacyclin-related | 1 |
| 347 | quinolone-related | 1 |
| 348 | quit-day | 1 |
| 349 | re-operation.no | 1 |
| 350 | reaction/rash-related | 1 |
| 351 | recist-assessed | 1 |
| 352 | regorafenib-related | 1 |
| 353 | regulatory-agency-defined | 1 |
| 354 | renal-associated | 1 |
| 355 | rf-driven | 1 |
| 356 | rh-endostatin-related | 1 |
| 357 | rhesus-d | 1 |
| 358 | sas-evoked | 1 |
| 359 | sd-induced | 1 |
| 360 | sexual-function-related | 1 |
| 361 | sham-continuous | 1 |
| 362 | sln-only | 1 |
| 363 | snpchip | 1 |
| 364 | spontaneous/elicited | 1 |
| 365 | stage-modified | 1 |
| 366 | sternheimer-malbin | 1 |
| 367 | stimulant-emergent | 1 |
| 368 | study-emergent | 1 |
| 369 | sud-mdd | 1 |
| 370 | sunchronic | 1 |
| 371 | supplement-associated | 1 |
| 372 | system/organ-class | 1 |
| 373 | tcr-mediated | 1 |
| 374 | tdap-associated | 1 |
| 375 | tdcpp-induced | 1 |
| 376 | thiopurine-related | 1 |
| 377 | ti-related | 1 |
| 378 | tiv-related | 1 |
| 379 | tracer-related | 1 |
| 380 | trif/irf3-mediated | 1 |
| 381 | triple-receptor | 1 |
| 382 | tronotropic | 1 |
| 383 | trpv1-receptor | 1 |
| 384 | ttf-related | 1 |
| 385 | urethritis-were | 1 |
| 386 | vacuole-targeted | 1 |
| 387 | vancomycin-related | 1 |
| 388 | varenicline-associated | 1 |
| 389 | vincristine-associated | 1 |
| 390 | viralstaphylococcal | 1 |
| 391 | vrl-associated | 1 |
| 392 | well-consolidated | 1 |
| 393 | zero-truncated | 1 |
| 1 | 'cardiometabolic | 1 |
| 2 | 'false | 9 |
| 3 | 'finger | 1 |
| 4 | 'hypersensitivity | 2 |
| 5 | 'medically | 6 |
| 6 | 'screened | 4 |
| 7 | -adrenergic-mediated | 1 |
| 8 | -improved | 1 |
| 9 | .haematological | 1 |
| 10 | .treatment-emergent | 1 |
| 11 | /s-rich | 1 |
| 12 | /serious | 2 |
| 13 | 0=very | 1 |
| 14 | 10/167 | 1 |
| 15 | 100. | 1 |
| 16 | 11,442 | 1 |
| 17 | 128/445 | 1 |
| 18 | 1bntiq-produced | 1 |
| 19 | 2,062 | 2 |
| 20 | 2-diphenylphosphinoyl-2,3-dien-1-ols | 1 |
| 21 | 25,946 | 1 |
| 22 | 3,679 | 2 |
| 23 | 38,530 | 1 |
| 24 | 5-loci | 2 |
| 25 | 60/625 | 1 |
| 26 | 69/70 | 1 |
| 27 | 7,736 | 1 |
| 28 | 94,459 | 1 |
| 29 | abstinence-related | 2 |
| 30 | acitretin-associated | 1 |
| 31 | acupuncture-related | 13 |
| 32 | adpkd-related | 3 |
| 33 | afatinib-related | 1 |
| 34 | agent-related | 3 |
| 35 | aht-induced | 1 |
| 36 | alkylaniline-induced | 1 |
| 37 | all-causality | 17 |
| 38 | almorexant-related | 1 |
| 39 | amiodarone-related | 3 |
| 40 | amotivation/asociality | 1 |
| 41 | anaesthesia-related | 10 |
| 42 | analgesia-related | 10 |
| 43 | analgesic-related | 1 |
| 44 | anthracyclines-induced | 1 |
| 45 | antibiotic-related | 16 |
| 46 | anticalcineurin | 1 |
| 47 | antiretroviral-related | 2 |
| 48 | any-grade | 7 |
| 49 | arousal-balanced | 1 |
| 50 | art-related | 11 |
| 51 | arv-related | 2 |
| 52 | available.other | 1 |
| 53 | aαc-induced | 2 |
| 54 | beta-agonist-mediated | 1 |
| 55 | bevacizumab-related | 16 |
| 56 | blaper-1 | 1 |
| 57 | brdu/nestin | 1 |
| 58 | c4d-negative | 1 |
| 59 | cabozantinib-associated | 2 |
| 60 | calcineurin-inhibitor-induced | 1 |
| 61 | canada-common | 1 |
| 62 | capecitabine-related | 3 |
| 63 | catumaxomab-related | 4 |
| 64 | cd34/cd133 | 1 |
| 65 | cd95-ligand | 1 |
| 66 | ces-related | 1 |
| 67 | cetuximab-related | 8 |
| 68 | chemical-level | 1 |
| 69 | chemotherapy-mediated | 2 |
| 70 | chemotherapy-related | 92 |
| 71 | ciliate-associated | 1 |
| 72 | cisplatin-associated | 8 |
| 73 | class-effect | 8 |
| 74 | classically-described | 1 |
| 75 | clinical/culture | 1 |
| 76 | clozapine-associated | 2 |
| 77 | cmab009-associated | 1 |
| 78 | cmi-linked | 1 |
| 79 | cmi-related | 3 |
| 80 | cml-related | 3 |
| 81 | cmv-dna | 3 |
| 82 | co2-reducing | 1 |
| 83 | coagulasa | 1 |
| 84 | coagulase | 86 |
| 85 | cochlear-vestibular | 1 |
| 86 | complication-related | 5 |
| 87 | continious | 1 |
| 88 | contrast-media-induced | 1 |
| 89 | conversion-related | 1 |
| 90 | cortisol-enforced | 1 |
| 91 | cq-related | 1 |
| 92 | crt-related | 3 |
| 93 | cv-related | 11 |
| 94 | d-late | 1 |
| 95 | denervation-related | 1 |
| 96 | depletion-related | 2 |
| 97 | desserting | 1 |
| 98 | dgge-band | 1 |
| 99 | diarrhea-attributable | 1 |
| 100 | dihydroethedium | 2 |
| 101 | dildl/lectin | 1 |
| 102 | discontinuation-emergent | 12 |
| 103 | discrepancy-related | 1 |
| 104 | dna-dna | 66 |
| 105 | dna–dna | 1 |
| 106 | docetaxel-specific | 1 |
| 107 | dose-limiting | 338 |
| 108 | drug-associated | 32 |
| 109 | drug-attributable | 6 |
| 110 | drug-attributed | 1 |
| 111 | drug-correlated | 1 |
| 112 | drug-related | 1,090 |
| 113 | drugs-related | 3 |
| 114 | drugs.when | 1 |
| 115 | dsra-based | 1 |
| 116 | dual-column | 2 |
| 117 | ecg-related | 3 |
| 118 | edema-related | 3 |
| 119 | eea-related | 1 |
| 120 | effectsserious | 1 |
| 121 | eight-color | 2 |
| 122 | ema-test | 1 |
| 123 | endoscopist-specific | 1 |
| 124 | enzymatiz | 1 |
| 125 | enzyme-containing | 1 |
| 126 | epidural-related | 3 |
| 127 | ertapenem-associated | 1 |
| 128 | erα- | 1 |
| 129 | estimate.in-hospital | 1 |
| 130 | ethanol-withdrawal-induced | 1 |
| 131 | event/serious | 1 |
| 132 | events/serious | 4 |
| 133 | exome-enriched | 1 |
| 134 | extra-hematologic | 1 |
| 135 | extra-striate | 1 |
| 136 | ezatiostat-related | 1 |
| 137 | ezn-4176-related | 1 |
| 138 | facts-the | 1 |
| 139 | false | 1,682 |
| 140 | fda-requested | 1 |
| 141 | feminising | 2 |
| 142 | follow-up.no | 2 |
| 143 | free-hand-drawn | 1 |
| 144 | g-gr-related | 1 |
| 145 | g3+ | 11 |
| 146 | g3/4 | 10 |
| 147 | gabapentin-related | 2 |
| 148 | gastrointestinal-related | 13 |
| 149 | gi-gu | 1 |
| 150 | gi-related | 7 |
| 151 | giemsa | 92 |
| 152 | gold-induced | 1 |
| 153 | grade≥3 | 7 |
| 154 | gram | 1,218 |
| 155 | gramm | 2 |
| 156 | grass-associated | 1 |
| 157 | gravidic | 4 |
| 158 | group.intraoperative | 1 |
| 159 | h2-oxidizing | 1 |
| 160 | haiderpur | 1 |
| 161 | hela-spiked | 1 |
| 162 | hematoxylin-eosine | 1 |
| 163 | heparin-related | 5 |
| 164 | her2-neu | 2 |
| 165 | heroin-related | 3 |
| 166 | hfpef-related | 2 |
| 167 | hfs-related | 1 |
| 168 | hla-dq2/8 | 4 |
| 169 | hla/dr | 1 |
| 170 | hp-immune | 1 |
| 171 | hql-related | 1 |
| 172 | hr-related | 2 |
| 173 | hsp90-related | 2 |
| 174 | hypothyroidism-induced | 3 |
| 175 | icatibant-related | 2 |
| 176 | ics-related | 2 |
| 177 | ifi-attributable | 1 |
| 178 | ifn-associated | 4 |
| 179 | ifnβ-associated | 1 |
| 180 | igpro20-related | 1 |
| 181 | ihc2+/bdish | 1 |
| 182 | il-2-receptor | 1 |
| 183 | illumina-based | 1 |
| 184 | immunosuppressant-induced | 1 |
| 185 | immunosuppression-related | 3 |
| 186 | imt-related | 1 |
| 187 | infusion-associated | 11 |
| 188 | infusion-related | 88 |
| 189 | injection-related | 42 |
| 190 | injection-site-related | 1 |
| 191 | integument-related | 6 |
| 192 | interferon-related | 3 |
| 193 | intervention-related | 66 |
| 194 | intolerable | 209 |
| 195 | intra-cup | 2 |
| 196 | investigator-reported | 36 |
| 197 | ipt-related | 3 |
| 198 | irinotecan-associated | 1 |
| 199 | isoniazid-related | 2 |
| 200 | isospora- | 1 |
| 201 | klinisk | 1 |
| 202 | klüver-barrera | 1 |
| 203 | knowledge.no | 1 |
| 204 | l-carnitine-related | 1 |
| 205 | la-related | 2 |
| 206 | lactation-long | 1 |
| 207 | lamotrigine-attributed | 3 |
| 208 | laronidase-related | 1 |
| 209 | leflunomide-associated | 1 |
| 210 | leuco-esterase | 1 |
| 211 | linifanib-related | 2 |
| 212 | lipodystrophy-related | 2 |
| 213 | lobene | 27 |
| 214 | lorcaserin-related | 1 |
| 215 | low-arousal | 3 |
| 216 | mannitol-related | 1 |
| 217 | me-cya-induced | 1 |
| 218 | medication-related | 129 |
| 219 | membrane-less | 1 |
| 220 | metabolic-related | 5 |
| 221 | mild/absent | 1 |
| 222 | mineralocorticoid-related | 2 |
| 223 | minitura | 1 |
| 224 | minor-related | 1 |
| 225 | mirtazapine-related | 1 |
| 226 | moderately-strong | 1 |
| 227 | monoviral | 1 |
| 228 | morphine-related | 28 |
| 229 | mtx-associated | 1 |
| 230 | multi-gated | 1 |
| 231 | muscle-associated | 4 |
| 232 | muscle-related | 41 |
| 233 | myd88/pi3k-directed | 1 |
| 234 | m₂r-mediated | 3 |
| 235 | ncic-tc | 1 |
| 236 | negative-her2 | 3 |
| 237 | netilmicin-induced | 1 |
| 238 | nevirapine-associated | 2 |
| 239 | nevirapine-induced | 2 |
| 240 | newer-design | 1 |
| 241 | next-generation | 153 |
| 242 | niacin-associated | 1 |
| 243 | nick-end | 47 |
| 244 | nicked-end | 1 |
| 245 | nih-defined | 1 |
| 246 | nissel | 1 |
| 247 | no-gi | 2 |
| 248 | nocebo-driven | 1 |
| 249 | non-haematological | 46 |
| 250 | non-hematological | 51 |
| 251 | nonanosmic | 2 |
| 252 | nonbleached | 1 |
| 253 | nonhematologic | 77 |
| 254 | nonhematological | 20 |
| 255 | nonlaboratory | 4 |
| 256 | nonmortal | 1 |
| 257 | nonnocturnal | 1 |
| 258 | nonpregnancy-specific | 1 |
| 259 | ntcp-predicted | 1 |
| 260 | nut-related | 2 |
| 261 | o-antigenic | 2 |
| 262 | ocular/non-ocular | 1 |
| 263 | oil-red-o | 4 |
| 264 | omalizumab-related | 1 |
| 265 | onabotulinumtoxina-associated | 2 |
| 266 | opioid-related | 116 |
| 267 | opioid-type | 1 |
| 268 | over-detect | 1 |
| 269 | overuse-related | 1 |
| 270 | p2xv/trpv1 | 1 |
| 271 | pacemaker-related | 1 |
| 272 | palifermin-related | 1 |
| 273 | pamidronate-related | 1 |
| 274 | pancreatitis/glucose | 1 |
| 275 | panss-rated | 1 |
| 276 | papanicoulau | 1 |
| 277 | past-treatment | 1 |
| 278 | pazopanib-related | 1 |
| 279 | pdm-style | 2 |
| 280 | pemetrexed-related | 2 |
| 281 | pf-3512676-related | 1 |
| 282 | photoaffinity | 3 |
| 283 | pi-associated | 7 |
| 284 | pld-associated | 1 |
| 285 | pneumoperitoneus | 1 |
| 286 | port-wine | 19 |
| 287 | positive-false | 1 |
| 288 | positive/false | 1 |
| 289 | possibly-related | 1 |
| 290 | post-cpoe | 3 |
| 291 | ppar-related | 1 |
| 292 | pre-intubation | 3 |
| 293 | pre-writing | 1 |
| 294 | prepharmacy | 1 |
| 295 | presented.serious | 1 |
| 296 | prilocaine-related | 1 |
| 297 | product-related | 23 |
| 298 | program-related | 3 |
| 299 | prone-related | 1 |
| 300 | prostacyclin-related | 1 |
| 301 | provider-rated | 3 |
| 302 | psychiatric-related | 6 |
| 303 | pump-related | 5 |
| 304 | quinolone-related | 1 |
| 305 | quit-day | 1 |
| 306 | radiation-related | 30 |
| 307 | radiochemotherapy-related | 4 |
| 308 | re-operation.no | 1 |
| 309 | reaction/rash-related | 1 |
| 310 | recist-assessed | 1 |
| 311 | regimen-related | 13 |
| 312 | regorafenib-related | 1 |
| 313 | regulatory-agency-defined | 1 |
| 314 | renal-associated | 1 |
| 315 | renal-related | 23 |
| 316 | rf-driven | 1 |
| 317 | rh-endostatin-related | 1 |
| 318 | rhesus-d | 1 |
| 319 | ribavirin-related | 2 |
| 320 | rose-bengal | 2 |
| 321 | rsv-rna | 4 |
| 322 | rt-related | 12 |
| 323 | sas-evoked | 1 |
| 324 | sca-related | 3 |
| 325 | sd-induced | 1 |
| 326 | self-attributed | 3 |
| 327 | sexual-function-related | 1 |
| 328 | sham-continuous | 1 |
| 329 | slit-related | 2 |
| 330 | sln-only | 1 |
| 331 | snpchip | 1 |
| 332 | snpstream | 2 |
| 333 | solicited | 282 |
| 334 | spontaneous/elicited | 1 |
| 335 | ssri-related | 6 |
| 336 | stage-modified | 1 |
| 337 | state-related | 7 |
| 338 | sternheimer-malbin | 1 |
| 339 | stimulant-emergent | 1 |
| 340 | stimulant-related | 3 |
| 341 | study-emergent | 1 |
| 342 | study-related | 52 |
| 343 | sud-mdd | 1 |
| 344 | sunchronic | 1 |
| 345 | supplement-associated | 1 |
| 346 | sypro-ruby | 2 |
| 347 | system-related | 36 |
| 348 | system/organ-class | 1 |
| 349 | systemically-mediated | 2 |
| 350 | ta-related | 2 |
| 351 | tamoxifen-related | 4 |
| 352 | tcr-mediated | 1 |
| 353 | tdap-associated | 1 |
| 354 | tdcpp-induced | 1 |
| 355 | temsirolimus-related | 6 |
| 356 | therapy-associated | 19 |
| 357 | therapy-related | 90 |
| 358 | thiopurine-related | 1 |
| 359 | ti-related | 1 |
| 360 | tick-associated | 2 |
| 361 | tinnitus-evoked | 3 |
| 362 | tiv-related | 1 |
| 363 | topiramate-associated | 3 |
| 364 | toxicity-related | 22 |
| 365 | tracer-related | 1 |
| 366 | trastuzumab-related | 3 |
| 367 | treatment-associated | 83 |
| 368 | treatment-emergent | 870 |
| 369 | treatment-limiting | 29 |
| 370 | treatment-modifying | 3 |
| 371 | treatment-related | 1,713 |
| 372 | treatment-unrelated | 3 |
| 373 | trif/irf3-mediated | 1 |
| 374 | triple-receptor | 1 |
| 375 | tronotropic | 1 |
| 376 | trpv1-receptor | 1 |
| 377 | ttf-related | 1 |
| 378 | tyrosine-hydroxylase | 3 |
| 379 | unsolicited | 106 |
| 380 | urethritis-were | 1 |
| 381 | vaccination-related | 10 |
| 382 | vaccine-associated | 13 |
| 383 | vaccine-related | 112 |
| 384 | vacuole-targeted | 1 |
| 385 | vancomycin-associated | 3 |
| 386 | vancomycin-related | 1 |
| 387 | varenicline-associated | 1 |
| 388 | vector-related | 2 |
| 389 | vincristine-associated | 1 |
| 390 | viralstaphylococcal | 1 |
| 391 | vrl-associated | 1 |
| 392 | well-consolidated | 1 |
| 393 | zero-truncated | 1 |
| 1 | g3+ | 11 |
| 2 | isospora- | 1 |
| 3 | erα- | 1 |
| 4 | 100. | 1 |
| 5 | 38,530 | 1 |
| 6 | 69/70 | 1 |
| 7 | blaper-1 | 1 |
| 8 | p2xv/trpv1 | 1 |
| 9 | 11,442 | 1 |
| 10 | 2,062 | 2 |
| 11 | negative-her2 | 3 |
| 12 | cd34/cd133 | 1 |
| 13 | grade≥3 | 7 |
| 14 | g3/4 | 10 |
| 15 | 60/625 | 1 |
| 16 | 128/445 | 1 |
| 17 | 7,736 | 1 |
| 18 | 25,946 | 1 |
| 19 | 10/167 | 1 |
| 20 | hla-dq2/8 | 4 |
| 21 | 94,459 | 1 |
| 22 | 3,679 | 2 |
| 23 | dna-dna | 66 |
| 24 | cmv-dna | 3 |
| 25 | dna–dna | 1 |
| 26 | rsv-rna | 4 |
| 27 | klüver-barrera | 1 |
| 28 | minitura | 1 |
| 29 | coagulasa | 1 |
| 30 | giemsa | 92 |
| 31 | gravidic | 4 |
| 32 | docetaxel-specific | 1 |
| 33 | endoscopist-specific | 1 |
| 34 | nonpregnancy-specific | 1 |
| 35 | extra-hematologic | 1 |
| 36 | nonhematologic | 77 |
| 37 | 'cardiometabolic | 1 |
| 38 | nonanosmic | 2 |
| 39 | o-antigenic | 2 |
| 40 | sunchronic | 1 |
| 41 | tronotropic | 1 |
| 42 | ncic-tc | 1 |
| 43 | rhesus-d | 1 |
| 44 | sud-mdd | 1 |
| 45 | classically-described | 1 |
| 46 | arousal-balanced | 1 |
| 47 | cortisol-enforced | 1 |
| 48 | contrast-media-induced | 1 |
| 49 | me-cya-induced | 1 |
| 50 | aαc-induced | 2 |
| 51 | gold-induced | 1 |
| 52 | sd-induced | 1 |
| 53 | alkylaniline-induced | 1 |
| 54 | nevirapine-induced | 2 |
| 55 | ethanol-withdrawal-induced | 1 |
| 56 | hypothyroidism-induced | 3 |
| 57 | netilmicin-induced | 1 |
| 58 | tdcpp-induced | 1 |
| 59 | calcineurin-inhibitor-induced | 1 |
| 60 | anthracyclines-induced | 1 |
| 61 | aht-induced | 1 |
| 62 | immunosuppressant-induced | 1 |
| 63 | 1bntiq-produced | 1 |
| 64 | nonbleached | 1 |
| 65 | exome-enriched | 1 |
| 66 | stage-modified | 1 |
| 67 | hela-spiked | 1 |
| 68 | cmi-linked | 1 |
| 69 | sas-evoked | 1 |
| 70 | tinnitus-evoked | 3 |
| 71 | 'screened | 4 |
| 72 | nih-defined | 1 |
| 73 | regulatory-agency-defined | 1 |
| 74 | illumina-based | 1 |
| 75 | dsra-based | 1 |
| 76 | recist-assessed | 1 |
| 77 | zero-truncated | 1 |
| 78 | well-consolidated | 1 |
| 79 | multi-gated | 1 |
| 80 | cmab009-associated | 1 |
| 81 | onabotulinumtoxina-associated | 2 |
| 82 | cabozantinib-associated | 2 |
| 83 | pld-associated | 1 |
| 84 | leflunomide-associated | 1 |
| 85 | muscle-associated | 4 |
| 86 | vaccine-associated | 13 |
| 87 | varenicline-associated | 1 |
| 88 | nevirapine-associated | 2 |
| 89 | clozapine-associated | 2 |
| 90 | vincristine-associated | 1 |
| 91 | ciliate-associated | 1 |
| 92 | topiramate-associated | 3 |
| 93 | drug-associated | 32 |
| 94 | pi-associated | 7 |
| 95 | tick-associated | 2 |
| 96 | renal-associated | 1 |
| 97 | vrl-associated | 1 |
| 98 | ertapenem-associated | 1 |
| 99 | irinotecan-associated | 1 |
| 100 | ifn-associated | 4 |
| 101 | niacin-associated | 1 |
| 102 | vancomycin-associated | 3 |
| 103 | cisplatin-associated | 8 |
| 104 | acitretin-associated | 1 |
| 105 | infusion-associated | 11 |
| 106 | tdap-associated | 1 |
| 107 | grass-associated | 1 |
| 108 | supplement-associated | 1 |
| 109 | treatment-associated | 83 |
| 110 | mtx-associated | 1 |
| 111 | therapy-associated | 19 |
| 112 | ifnβ-associated | 1 |
| 113 | trif/irf3-mediated | 1 |
| 114 | -adrenergic-mediated | 1 |
| 115 | tcr-mediated | 1 |
| 116 | m₂r-mediated | 3 |
| 117 | beta-agonist-mediated | 1 |
| 118 | systemically-mediated | 2 |
| 119 | chemotherapy-mediated | 2 |
| 120 | igpro20-related | 1 |
| 121 | hsp90-related | 2 |
| 122 | ezn-4176-related | 1 |
| 123 | pf-3512676-related | 1 |
| 124 | sca-related | 3 |
| 125 | eea-related | 1 |
| 126 | analgesia-related | 10 |
| 127 | anaesthesia-related | 10 |
| 128 | la-related | 2 |
| 129 | edema-related | 3 |
| 130 | ta-related | 2 |
| 131 | cetuximab-related | 8 |
| 132 | catumaxomab-related | 4 |
| 133 | bevacizumab-related | 16 |
| 134 | omalizumab-related | 1 |
| 135 | trastuzumab-related | 3 |
| 136 | linifanib-related | 2 |
| 137 | pazopanib-related | 1 |
| 138 | regorafenib-related | 1 |
| 139 | afatinib-related | 1 |
| 140 | metabolic-related | 5 |
| 141 | psychiatric-related | 6 |
| 142 | analgesic-related | 1 |
| 143 | antibiotic-related | 16 |
| 144 | pemetrexed-related | 2 |
| 145 | mineralocorticoid-related | 2 |
| 146 | opioid-related | 116 |
| 147 | isoniazid-related | 2 |
| 148 | adpkd-related | 3 |
| 149 | abstinence-related | 2 |
| 150 | muscle-related | 41 |
| 151 | prilocaine-related | 1 |
| 152 | capecitabine-related | 3 |
| 153 | vaccine-related | 112 |
| 154 | morphine-related | 28 |
| 155 | mirtazapine-related | 1 |
| 156 | thiopurine-related | 1 |
| 157 | l-carnitine-related | 1 |
| 158 | quinolone-related | 1 |
| 159 | amiodarone-related | 3 |
| 160 | prone-related | 1 |
| 161 | acupuncture-related | 13 |
| 162 | laronidase-related | 1 |
| 163 | overuse-related | 1 |
| 164 | pamidronate-related | 1 |
| 165 | state-related | 7 |
| 166 | injection-site-related | 1 |
| 167 | hfpef-related | 2 |
| 168 | ttf-related | 1 |
| 169 | ecg-related | 3 |
| 170 | drug-related | 1,090 |
| 171 | reaction/rash-related | 1 |
| 172 | gi-related | 7 |
| 173 | cmi-related | 3 |
| 174 | ssri-related | 6 |
| 175 | ti-related | 1 |
| 176 | renal-related | 23 |
| 177 | gastrointestinal-related | 13 |
| 178 | antiretroviral-related | 2 |
| 179 | epidural-related | 3 |
| 180 | cml-related | 3 |
| 181 | mannitol-related | 1 |
| 182 | hql-related | 1 |
| 183 | program-related | 3 |
| 184 | system-related | 36 |
| 185 | tamoxifen-related | 4 |
| 186 | regimen-related | 13 |
| 187 | vancomycin-related | 1 |
| 188 | prostacyclin-related | 1 |
| 189 | palifermin-related | 1 |
| 190 | heroin-related | 3 |
| 191 | heparin-related | 5 |
| 192 | lorcaserin-related | 1 |
| 193 | ribavirin-related | 2 |
| 194 | rh-endostatin-related | 1 |
| 195 | gabapentin-related | 2 |
| 196 | conversion-related | 1 |
| 197 | immunosuppression-related | 3 |
| 198 | infusion-related | 88 |
| 199 | medication-related | 129 |
| 200 | complication-related | 5 |
| 201 | radiation-related | 30 |
| 202 | vaccination-related | 10 |
| 203 | denervation-related | 1 |
| 204 | injection-related | 42 |
| 205 | sexual-function-related | 1 |
| 206 | depletion-related | 2 |
| 207 | intervention-related | 66 |
| 208 | interferon-related | 3 |
| 209 | pump-related | 5 |
| 210 | cq-related | 1 |
| 211 | ppar-related | 1 |
| 212 | tracer-related | 1 |
| 213 | pacemaker-related | 1 |
| 214 | g-gr-related | 1 |
| 215 | hr-related | 2 |
| 216 | minor-related | 1 |
| 217 | vector-related | 2 |
| 218 | ics-related | 2 |
| 219 | ces-related | 1 |
| 220 | hfs-related | 1 |
| 221 | drugs-related | 3 |
| 222 | temsirolimus-related | 6 |
| 223 | ezatiostat-related | 1 |
| 224 | product-related | 23 |
| 225 | slit-related | 2 |
| 226 | imt-related | 1 |
| 227 | icatibant-related | 2 |
| 228 | stimulant-related | 3 |
| 229 | almorexant-related | 1 |
| 230 | agent-related | 3 |
| 231 | treatment-related | 1,713 |
| 232 | integument-related | 6 |
| 233 | ipt-related | 3 |
| 234 | rt-related | 12 |
| 235 | art-related | 11 |
| 236 | crt-related | 3 |
| 237 | nut-related | 2 |
| 238 | cv-related | 11 |
| 239 | tiv-related | 1 |
| 240 | arv-related | 2 |
| 241 | discrepancy-related | 1 |
| 242 | study-related | 52 |
| 243 | lipodystrophy-related | 2 |
| 244 | possibly-related | 1 |
| 245 | therapy-related | 90 |
| 246 | chemotherapy-related | 92 |
| 247 | radiochemotherapy-related | 4 |
| 248 | toxicity-related | 22 |
| 249 | treatment-unrelated | 3 |
| 250 | drug-correlated | 1 |
| 251 | provider-rated | 3 |
| 252 | panss-rated | 1 |
| 253 | myd88/pi3k-directed | 1 |
| 254 | ntcp-predicted | 1 |
| 255 | vacuole-targeted | 1 |
| 256 | spontaneous/elicited | 1 |
| 257 | solicited | 282 |
| 258 | unsolicited | 106 |
| 259 | investigator-reported | 36 |
| 260 | fda-requested | 1 |
| 261 | lamotrigine-attributed | 3 |
| 262 | self-attributed | 3 |
| 263 | drug-attributed | 1 |
| 264 | -improved | 1 |
| 265 | dgge-band | 1 |
| 266 | cd95-ligand | 1 |
| 267 | nicked-end | 1 |
| 268 | nick-end | 47 |
| 269 | any-grade | 7 |
| 270 | facts-the | 1 |
| 271 | intolerable | 209 |
| 272 | diarrhea-attributable | 1 |
| 273 | drug-attributable | 6 |
| 274 | ifi-attributable | 1 |
| 275 | pdm-style | 2 |
| 276 | lobene | 27 |
| 277 | hematoxylin-eosine | 1 |
| 278 | port-wine | 19 |
| 279 | hp-immune | 1 |
| 280 | post-cpoe | 3 |
| 281 | opioid-type | 1 |
| 282 | urethritis-were | 1 |
| 283 | clinical/culture | 1 |
| 284 | coagulase | 86 |
| 285 | tyrosine-hydroxylase | 3 |
| 286 | leuco-esterase | 1 |
| 287 | false | 1,682 |
| 288 | 'false | 9 |
| 289 | positive-false | 1 |
| 290 | positive/false | 1 |
| 291 | pancreatitis/glucose | 1 |
| 292 | extra-striate | 1 |
| 293 | d-late | 1 |
| 294 | c4d-negative | 1 |
| 295 | group.intraoperative | 1 |
| 296 | co2-reducing | 1 |
| 297 | enzyme-containing | 1 |
| 298 | feminising | 2 |
| 299 | dose-limiting | 338 |
| 300 | treatment-limiting | 29 |
| 301 | pre-writing | 1 |
| 302 | desserting | 1 |
| 303 | treatment-modifying | 3 |
| 304 | h2-oxidizing | 1 |
| 305 | lactation-long | 1 |
| 306 | moderately-strong | 1 |
| 307 | /s-rich | 1 |
| 308 | ihc2+/bdish | 1 |
| 309 | 5-loci | 2 |
| 310 | no-gi | 2 |
| 311 | klinisk | 1 |
| 312 | viralstaphylococcal | 1 |
| 313 | non-haematological | 46 |
| 314 | .haematological | 1 |
| 315 | non-hematological | 51 |
| 316 | nonhematological | 20 |
| 317 | rose-bengal | 2 |
| 318 | nonnocturnal | 1 |
| 319 | monoviral | 1 |
| 320 | low-arousal | 3 |
| 321 | estimate.in-hospital | 1 |
| 322 | nonmortal | 1 |
| 323 | nissel | 1 |
| 324 | chemical-level | 1 |
| 325 | snpstream | 2 |
| 326 | gram | 1,218 |
| 327 | gramm | 2 |
| 328 | dihydroethedium | 2 |
| 329 | drugs.when | 1 |
| 330 | rf-driven | 1 |
| 331 | nocebo-driven | 1 |
| 332 | newer-design | 1 |
| 333 | sternheimer-malbin | 1 |
| 334 | anticalcineurin | 1 |
| 335 | dildl/lectin | 1 |
| 336 | brdu/nestin | 1 |
| 337 | dual-column | 2 |
| 338 | pre-intubation | 3 |
| 339 | next-generation | 153 |
| 340 | canada-common | 1 |
| 341 | free-hand-drawn | 1 |
| 342 | oil-red-o | 4 |
| 343 | knowledge.no | 1 |
| 344 | re-operation.no | 1 |
| 345 | follow-up.no | 2 |
| 346 | snpchip | 1 |
| 347 | intra-cup | 2 |
| 348 | cochlear-vestibular | 1 |
| 349 | ocular/non-ocular | 1 |
| 350 | hla/dr | 1 |
| 351 | 'finger | 1 |
| 352 | available.other | 1 |
| 353 | eight-color | 2 |
| 354 | trpv1-receptor | 1 |
| 355 | il-2-receptor | 1 |
| 356 | triple-receptor | 1 |
| 357 | haiderpur | 1 |
| 358 | 2-diphenylphosphinoyl-2,3-dien-1-ols | 1 |
| 359 | system/organ-class | 1 |
| 360 | membrane-less | 1 |
| 361 | pneumoperitoneus | 1 |
| 362 | continious | 1 |
| 363 | presented.serious | 1 |
| 364 | /serious | 2 |
| 365 | events/serious | 4 |
| 366 | event/serious | 1 |
| 367 | effectsserious | 1 |
| 368 | sham-continuous | 1 |
| 369 | class-effect | 8 |
| 370 | over-detect | 1 |
| 371 | discontinuation-emergent | 12 |
| 372 | stimulant-emergent | 1 |
| 373 | treatment-emergent | 870 |
| 374 | .treatment-emergent | 1 |
| 375 | study-emergent | 1 |
| 376 | past-treatment | 1 |
| 377 | mild/absent | 1 |
| 378 | ema-test | 1 |
| 379 | papanicoulau | 1 |
| 380 | her2-neu | 2 |
| 381 | gi-gu | 1 |
| 382 | quit-day | 1 |
| 383 | sypro-ruby | 2 |
| 384 | prepharmacy | 1 |
| 385 | 'medically | 6 |
| 386 | sln-only | 1 |
| 387 | 0=very | 1 |
| 388 | nonlaboratory | 4 |
| 389 | amotivation/asociality | 1 |
| 390 | all-causality | 17 |
| 391 | photoaffinity | 3 |
| 392 | 'hypersensitivity | 2 |
| 393 | enzymatiz | 1 |